A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST)
- PMID: 39422935
- PMCID: PMC12279255
- DOI: 10.3233/JAD-230635
A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST)
Abstract
Alzheimer's disease (AD) is a leading cause of mortality and morbidity among aging populations worldwide. Despite arduous research efforts, treatment options for this devastating neurodegenerative disease are limited. Sleep disturbances, through their link to changes in neural excitability and impaired clearance of interstitial abnormal protein aggregates, are a key risk factor for the development of AD. Research also suggests that the neuroprotective effects of sleep are particularly active during slow wave sleep. Given the strong link between sleep disturbance and AD, targeting sleep in the prodromal stages of AD, such as in mild cognitive impairment (MCI), represents a promising avenue for slowing the onset of AD-related cognitive decline. In efforts to improve sleep in older individuals, several pharmacologic approaches have been employed, but many pose safety risks, concern for worsening cognitive function, and fail to effectively target slow wave sleep. Trazodone, a safe and widely used drug in the older adult population, has shown promise in inducing slow wave sleep in older adults, but requires more rigorous research to understand its effects on sleep and cognition in the prodromal stages of AD. In this review, we present the rationale and study design for our randomized, double-bind, placebo-controlled, crossover trial (NCT05282550) investigating the effects of trazodone on sleep and cognition in 100 older adults with amnestic MCI and sleep complaints.
Keywords: Alzheimer’s disease; circadian rhythms; hippocampus; mild cognitive impairment; sleep; trazodone.
Conflict of interest statement
P. Rosenberg received support in the form of grant funding from the National Institute of Aging Alzheimer’s Association, Lilly, Functional Neuromodulation, Vaccinex, the Alzheimer’s Disease Cooperative Study (ADCS), Alzheimer’s Disease Trials Research Institute (ATRI), and the Alzheimer’s Clinical Trials Consortium (ACTC); he has served as a consultant to GLG, Leerink, Otsuka, Avanir, ITI, IQVIA, Food and Drug Administration, Cerevel, Bioxcel, Sunovion, and Acadia. B.
A. Spira received payment for serving as a consultant for Merck and received honoraria from Springer Nature Switzerland AG for guest editing special issues of
Figures

References
-
- 2023 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2023;19(4):1598–1695. https://doi.org/10.1002/alz.13016. doi: 10.1002/alz.13016. - DOI - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical